Специалисту

Герминогенные опухоли

  1. Richie JP. Neoplasms of the testis, in Walsh PC et al. (eds). Campbell’s Urology. 7th ed. Philadelphia: Saunders, 1997: pp. 2411–52.
  2. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112(2):232–46.
    http://www.ncbi.nlm.nih.gov/pubmed/6106385
  3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170(1):5–11.
    http://www.ncbi.nlm.nih.gov/pubmed/12796635
  4. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97(1):63–70.
    http://www.ncbi.nlm.nih.gov/pubmed/12491506
  5. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337(4):242–53.
    http://www.ncbi.nlm.nih.gov/pubmed/9227931
  6. Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, Jonas U. Alterations of the p53 tumour suppressor gene in carcinoma in situ of the testis. Cancer 1996;78(9):1958–66.
    http://www.ncbi.nlm.nih.gov/pubmed/8909317
  7. Looijenga LH, Gillis AJ, Stoop H, Hersmus R, Oosterhuis JW. Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumours. Int J Androl 2007;30(4):304–14; discussion 314–15.
    http://www.ncbi.nlm.nih.gov/pubmed/17573854
  8. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol 2005;18(Suppl 2):S51–S60.
    http://www.ncbi.nlm.nih.gov/pubmed/15761466
  9. Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, Munck-Hansen J, Rassmussen LH. Risk of bilateral testicular germ cell tumours in Denmark: 1960–1984. J Natl Cancer Inst 1991;83(19):1391–5.
    http://www.ncbi.nlm.nih.gov/pubmed/1656057
  10. Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264–74.
    http://www.ncbi.nlm.nih.gov/pubmed/8740739
  11. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer. Cancer 1997;80(10):1954–60.
    http://www.ncbi.nlm.nih.gov/pubmed/9366298
  12. Forman D, Oliver RT, Brett AR, Marsh SG, Moses JH, Bodmer JG, Chilvers CE, Pike MC. Familial testicular cancer: a report of the UK family register, estimation of risk and a HLA class 1 sib-pair analysis. Br J Cancer 1992;65(2):255–62.
    http://www.ncbi.nlm.nih.gov/pubmed/1739626
  13. Weestergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 1996;66(5):627–31.
    http://www.ncbi.nlm.nih.gov/pubmed/8647624
  14. Dieckmann KP, Loy V, Buttner P. Prevalence of bilateral germ cell tumours and early detection based on contralateral testicular intra-epithelial neoplasia. Br J Urol 1993;71(3):340–5.
    http://www.ncbi.nlm.nih.gov/pubmed/8386582
  15. Dieckmann KP, Pichlmeier U. Is risk of testicular cancer related to the body size? Eur Urol 2002;42(6):564–9.
    http://www.ncbi.nlm.nih.gov/pubmed/12477651
  16. Wanderas EH, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway 1955–1992. Eur J Cancer 1995;31A(12):2044–8.
    http://www.ncbi.nlm.nih.gov/pubmed/8562163
  17. Jones A, Fergus JN, Chapman J, Houghton L. Is surveillance for stage I germ cell tumours of the testis appropiate outside a specialist centre? BJU Int 1999;84(1):79–84.
    http://www.ncbi.nlm.nih.gov/pubmed/10444129
  18. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Ney Lallemand E, Kaye SB. Impact of the treating institution on survival of patients with poor-prognosis nonseminoma. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Working Party. J Natl Cancer Inst 1999;91(10):839–46.
    http://www.ncbi.nlm.nih.gov/pubmed/10340903
  19. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G. Guidelines on testicular cancer. Eur Urol 2005;48(6):885–94.
    http://www.ncbi.nlm.nih.gov/pubmed/16126333
  20. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol
    2002;20(22):4448–52.
    http://www.ncbi.nlm.nih.gov/pubmed/12431967
  21. Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidencebased systematic review. Cancer Treat Rev 2002;28(5):237–53.
    http://www.ncbi.nlm.nih.gov/pubmed/12435371
  22. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-St?hl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Foss? SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Uro. 2008 Mar;53(3):478–96.
    http://www.ncbi.nlm.nih.gov/pubmed/18191324
  23. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin- St?hl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Foss? SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008 Mar;53(3):497–513.
    http://www.ncbi.nlm.nih.gov/pubmed/18191015
  24. Deutsche Krebsgesellschaft: Leitlinie zur Diagnostik und Therapie von Hodentumouren auf Grundlage evidenzbasierter Medizin (EBM). Souchon R, Schmoll HJ, Krege S, for the German Testicular Cancer Study Group (eds). Qualit?tsicherung in der Onkologie. 1st edn. M?nchen – Bern – Wien – New York – Zuckschwerdt, 2002. [German Cancer Society: Evidence-based guideline for the assessment and treatment of testicular tumours] [article in German].
  25. The Royal College of Radiologists’ Clinical Oncology Network in partnership with Scottish Intercollegiate Network 2000. Guidelines on the management of adult testicular germ cell tumours. Clin Oncol (R Coll Radiol) 2000;12(5):S173–S210.
    http://www.ncbi.nlm.nih.gov/pubmed/11315727
  26. Diagnostiek en behandeling van kiemceltumouren van de testis. Richtlijnen Nederlandse Vereniging voor urologie. No 14. [Diagnosis and treatment of testicular germ cell tumours. Dutch Urological Society guidelines] [article in Dutch].
  27. Segal R, Lukka H, Klotz LH, Eady A, Bestic N, Johnston M; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group. Surveillance programs for early stage nonseminomatous testicular cancer: a practice guideline. Can J Urol 2001;8(1):1184–92.
    http://www.ncbi.nlm.nih.gov/pubmed/11268306
  28. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998.
    http://www.cebm.net/index.aspx?o=1025 [accessed February 2009]
  29. WHO histological classification of testis tumours, In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology & Genetics. Tumours of the urinary system and male genital organs. Lyons: IARC Press, 2004: 218, pp. 250–262.
  30. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, Alba E, Satre J, Aparicio J, Fernandez A, Barnadas A, Terrassa J, Saenz A, Almenar D, Lopez-Brea M, Climent MA, Sanchez MA, Lasso de la Vega R, Berenguer G, Perez X; Spanish Germ-Cell Cancer Group (GG). Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42(6):553–62.
    http://www.ncbi.nlm.nih.gov/pubmed/12477650
  31. Skakkebaek NE. Possible carcinoma-in-situ of the testis. Lancet 1972;2(7776):516–7.
    http://www.ncbi.nlm.nih.gov/pubmed/4115573
  32. Richie JP, Birnholz J, Garnick MB. Ultrasonography as a diagnostic adjunct for the evaluation of masses in the scrotum. Surg Gynecol Obstet 1982;154(5):695–8.
    http://www.ncbi.nlm.nih.gov/pubmed/7071705
  33. Doherty FJ. Ultrasound of the nonacute scrotum, in Raymond HW et al. (eds). Seminars in Ultrasound, CT and MRI. New York: WB Saunders, 1991, pp. 131–156.
  34. Comiter CU, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR. Nonpalpable intratesticular masses detected sonographically. J Urol 1995;154(4):1367–9. http://www.ncbi.nlm.nih.gov/pubmed/7658540
  35. Friedrich M, Claussen CD, Felix R. Immersion ultrasound of testicular pathology. Radiology 1981;141(1):235–7
    http://www.ncbi.nlm.nih.gov/pubmed/7291531
  36. Glazer HS, Lee JKT, Melson GL, McClennan BL. Sonographic detection of occult testicular neoplasm. ARJ Am J Roentgenol 1982;138(4):673–5.
    http://www.ncbi.nlm.nih.gov/pubmed/6978030
  37. Bockrath JM, Schaeffer AJ, Kiess MS, Nieman HL. Ultrasound Identification of impalpable testicle tumour. J Urol 1983;130(2):355–6.
    http://www.ncbi.nlm.nih.gov/pubmed/6876291
  38. Shawker TH, Javadpour N, O’Leary T, Shapiro E, Krudy AG. Ultrasonographic detection of ‘burnedout’ primary testicular germ cell tumours in clinically normal testes. J Ultrasound Med 1983;2(10):477–9.
    http://www.ncbi.nlm.nih.gov/pubmed/6313958
  39. Lenz S, Giwercman A, Skakkebaek NE, Bruun E, Frimodt-Moller C. Ultrasound in detection of early neoplasia of the testis. Int J Androl 1987;10(1):187–90.
    http://www.ncbi.nlm.nih.gov/pubmed/2884185
  40. Thurnher S, Hricak H, Carroll PR, Pobiel RS, Filly RA. Imaging the testis: comparison between MR imaging and US. Radiology 1988;167(3):631–6.
    http://www.ncbi.nlm.nih.gov/pubmed/3283834
  41. Mattrey RF. Magnetic resonance imaging of the scrotum. Semin Ultrasound CT MR 1991;12(2):95–108.
    http://www.ncbi.nlm.nih.gov/pubmed/1863480
  42. Rholl KS, Lee JKT, Ling D, Heiken JP, Glazer HS. MR imaging of the scrotum with a high resolution surface coil. Radiology 1987;163(1):99–103.
    http://www.ncbi.nlm.nih.gov/pubmed/3547497
  43. Johnson JO, Mattrey RF, Phillipson J. Differentiation of seminomatous from nonseminomatous testicular tumours by MRI. AJR Am J Roentgenol 1990;154(3):539–43.
    http://www.ncbi.nlm.nih.gov/pubmed/2106218
  44. Klein EA. Tumour markers in testis cancer. Urol Clin North Am 1993;20(1):67–73.
    http://www.ncbi.nlm.nih.gov/pubmed/7679533
  45. Peyret C. Tumeurs du testicule. Synth?se et recommandations en onco-urologie. Prog Urol 1993;2:60–4. [Testicular tumours. Summary of onco-urological recommendations] [article in French].
  46. Javadpour N. The role of biologic markers in testicular cancer. Cancer 1980;45(7 Suppl):1755–61.
    http://www.ncbi.nlm.nih.gov/pubmed/6154517
  47. Heidenreich A, Weissbach L, Holth W, Albers P, Kliesch S, Kohrmann KU, Dieckmann KP. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumour of the testis. J Urol
    2001;166(6):2161–5.
    http://www.ncbi.nlm.nih.gov/pubmed/11696727
  48. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, Hansen SW, von der Maase H. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-insitu in the testis. J Clin Oncol 2002;20(6):1537–43.
    http://www.ncbi.nlm.nih.gov/pubmed/11896102
  49. Heidenreich A, Holtl W, Albrecht W, Pont J, Engelmann UH. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997;79(2):253–7.
    http://www.ncbi.nlm.nih.gov/pubmed/9052478
  50. Weissbach L. Organ preserving surgery of malignant germ cell tumours. J Urol 1995;153(1):90–3.
    http://www.ncbi.nlm.nih.gov/pubmed/7966800
  51. Dieckmann KP, Loy V. Prevalence of contralatral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996;14(12):3126–32.
    http://www.ncbi.nlm.nih.gov/pubmed/8955658
  52. Von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE. Carcinoma-in-situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 1986; 293(6559):1398–401.
    http://www.ncbi.nlm.nih.gov/pubmed/3026550
  53. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP. Intratubular germ cell neoplasia of contralateral testis in testicular cancer: defining a high risk group. J Urol 1998;160(4):1353–7.
    http://www.ncbi.nlm.nih.gov/pubmed/9751353
  54. Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra J, Borras J, Villavicencio H, Leiva O, Cortes-Funes H. Incidence of contralateral germ cell testicular tumours in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol 2004;171(1):164–7.
    http://www.ncbi.nlm.nih.gov/pubmed/14665868
  55. Herr HW, Sheinfeld J. Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urol 1997;158(4):1331–4.
    http://www.ncbi.nlm.nih.gov/pubmed/9302113
  56. Albers P, Goll A, Bierhoff E, Schoeneich G, Muller SC. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumours. Urology 1999;54(4):714–8.
    http://www.ncbi.nlm.nih.gov/pubmed/10510934
  57. Giwercman A, Bruun E, Frimotd-Muller C, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol
    1989;142(4):998–1001.
    http://www.ncbi.nlm.nih.gov/pubmed/2571738
  58. Heidenreich A, Moul JW. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Sem Urol Oncol 2002;20(4):234–8.
    http://www.ncbi.nlm.nih.gov/pubmed/12489055
  59. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 2007:51(1):175–83; discussion 183–5.
    http://www.ncbi.nlm.nih.gov/pubmed/16814456
  60. Kliesch S, Thomaidis T, Sch?tte B, Puhse G, Kater B, Roth S, Bergmann M. Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS 2003;111(1):70–4.
    http://www.ncbi.nlm.nih.gov/pubmed/12752238
  61. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V; German Testicular Cancer Study Group. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia:
    preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 2003;88(6):828–31.
    http://www.ncbi.nlm.nih.gov/pubmed/12644817
  62. Leibovitch I, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154(5):1759–63.
    http://www.ncbi.nlm.nih.gov/pubmed/7563341
  63. Jing B, Wallace S, Zornoza J. Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography. Radiol Clin North Am 1982;20(3):511–30.
    http://www.ncbi.nlm.nih.gov/pubmed/7051132
  64. Husband JE, Barrett A, Peckham MJ. Evaluation of computed tomography in the management of testicular teratoma. Br J Urol 1981;53(2):179–83.
    http://www.ncbi.nlm.nih.gov/pubmed/7237052
  65. Swanson DA. Role of retroperitoneal lymphadenectomy (RLDN) when patients with nonseminomatous germ cell testicular tumours are at high risk of needing lymph node surgery plus chemotherapy, in Donohue JP (ed.). Lymph Node Surgery in Urology. International Society of Urology Reports. Oxford: Isis Medical Media, 1995, pp. 133–140.
  66. Ellis JH, Blies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. J Comput Assist Tomogr 1984;8(4):709–9.
    http://www.ncbi.nlm.nih.gov/pubmed/6539790
  67. See WA, Hoxie L. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 1993;150(3):874–8.
    http://www.ncbi.nlm.nih.gov/pubmed/8345604
  68. Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Gunther RW, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?– Results of a study in 50 patients. Urology 1999;54(5):900–4.
    http://www.ncbi.nlm.nih.gov/pubmed/10565755
  69. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumours. Urology 1999;53(4):808–11.
    http://www.ncbi.nlm.nih.gov/pubmed/10197862
  70. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22(6):1034–9.
    http://www.ncbi.nlm.nih.gov/pubmed/15020605
  71. Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 2002;89(6):549–56.
    http://www.ncbi.nlm.nih.gov/pubmed/11942962
  72. Sobin LH, Wittekind C (eds). TNM classification of malignant tumours. 6th edn. UICC/Wiley, 2002.
    http://www.wiley.com/
  73. Zagars GK. Management of stage I seminoma: radiotherapy, in Horwich A (ed.). Testicular Cancer: Investigation and Management. London: Chapman & Hall Medical, 1999, p. 99.
  74. Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fossa SD, Paus E. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of preand postorchidectomy serum tumour marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol
    1990;1(4):281–8.
    http://www.ncbi.nlm.nih.gov/pubmed/1702312
  75. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol
    1997;15(2):594–603.
    http://www.ncbi.nlm.nih.gov/pubmed/9053482
  76. Bokemeyer C, Schmoll HJ. Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J Cancer Res Clin Oncol 1996;122:575–84.
  77. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumours: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21(8):1505–12.
    http://www.ncbi.nlm.nih.gov/pubmed/12697874
  78. Petersen PM, Giwercman A, Skakkebaek NE, Rorth M. Gonadal function in men with testicular cancer. Semin Oncol 1998;25(2):224–33.
    http://www.ncbi.nlm.nih.gov/pubmed/9562456
  79. De Santis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment of long-term fertility in patients with germ-cell cancer. Int J Cancer 1999;83(6):864–5.
    http://www.ncbi.nlm.nih.gov/pubmed/10597213
  80. Jacobsen KD, Fossa SD, Bjoro TP, Aass N, Heilo A, Stenwig AE. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol 2002;42(3):229–38.
    http://www.ncbi.nlm.nih.gov/pubmed/12234507
  81. Kliesch S, Behre HM, Jurgens H, Nieschlag E. Cryopreservation of semen from adolescent patients with malignancies. Med Pediatr Oncol 1996;26(1):20–7.
    http://www.ncbi.nlm.nih.gov/pubmed/7494508
  82. Giwercman A, von der Maase H, Rorth M, Skakkebaek NE. Semen quality in testicular tumour and CIS in the contralateral testis. Lancet 1993;341(8841):384–5.
    http://www.ncbi.nlm.nih.gov/pubmed/8094162
  83. Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 1997;12(12):2830–35.
    http://www.ncbi.nlm.nih.gov/pubmed/9455863
  84. Spermon JR, Kiemeney LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumours. Fertil Steril 2003;79(Suppl 3):1543–9.
    http://www.ncbi.nlm.nih.gov/pubmed/12801557
  85. Nieschlag E, Behre HM. Pharmacology and clinical use of testosterone, in Nieschlag E, Behre HM (eds). Testosterone-Action, Deficiency, Substitution. Berlin–Heidelberg–New York: Springer, 1999, pp. 92–114.
  86. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am 1998 Aug;25(3):435–49.
    http://www.ncbi.nlm.nih.gov/pubmed/9728213
  87. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007;64(3):182–97.
    http://www.ncbi.nlm.nih.gov/pubmed/17644403
  88. Chung P, Parker C, panzarella T, Gospodarowicz MK, Jewett S, Milosevic MF, Catton CN, Bayley AJ, Tew-George B, Moore M, Sturgeon JF, Warde P. Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol 2002;9(5):1637–40.
    http://www.ncbi.nlm.nih.gov/pubmed/12431325
  89. Warde P, Jewett MAS. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998;25(3):425–33.
    http://www.ncbi.nlm.nih.gov/pubmed/9728212
  90. Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR; Spanish Germ Cell Cancer Cooperative Group (GG). Multicenter study evaluating a dual policy of postorchidectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867–72.
    http://www.ncbi.nlm.nih.gov/pubmed/12796024
  91. Sharda N, Kinsella T, Ritter M. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in earlystage testicular seminoma. J Clin Oncol 1996;14(11):2933–9.
    http://www.ncbi.nlm.nih.gov/pubmed/8918490
  92. Francis R, Bower M, Brunstrom G, Holden L, Newlands ES, Rustin GJS, Seckl MJ. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000;36(15):1925–32.
    http://www.ncbi.nlm.nih.gov/pubmed/11000572
  93. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M. Issues in the management of stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1997;39:S156.
  94. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;23–29;366(9482):293–300.
    http://www.ncbi.nlm.nih.gov/pubmed/16039331
  95. Aparicio J, Germ? JR, Garc?a del Muro X, Maroto P, Arranz JA, S?enz A, Barnadas A, Dorca J, Gum? J, Olmos D, Bast?s R, Carles J, Almenar D, S?nchez M, Paz-Ares L, Satr?stegui JJ, Mellado B, Balil A, L?pez-Brea M, S?nchez A; The Second Spanish Germ Cell Cancer Cooperative Group. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23(34):8717–23.
    http://www.ncbi.nlm.nih.gov/pubmed/16260698
  96. Schoffski P, H?hn N, Kowalski R, Classen J, Meisner C, Fechner G, Dieckmann K, Winkler C, Bamberg M. Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): Results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer. ASCO Annual Meeting Proceedings. Part 1. J Clin Oncol 2007;25(Suppl 18S):5050.
    http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_
    view&confID=47&abstractID=32158
  97. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17(4):1146.
    http://www.ncbi.nlm.nih.gov/pubmed/10561173
  98. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Naylor S, Tenning SP. A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE 18). Eur J Cancer
    2001;37(Suppl 6):S157, abstr 572.
  99. Melchior D, Hammer P, Fimmers R, Schuller H, Albers P. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res
    2001;21(4B):2989–93.
    http://www.ncbi.nlm.nih.gov/pubmed/11712799
  100. Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue PJ. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for followup. Clin Oncol (R Coll Radiol)
    2001;13(4):296–300.
    http://www.ncbi.nlm.nih.gov/pubmed/11554630
  101. Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. Clin Oncol 1993;11(3):415–24.
    http://www.ncbi.nlm.nih.gov/pubmed/8445415
  102. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD Jr. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89(19):1429–39.
    http://www.ncbi.nlm.nih.gov/pubmed/9326912
  103. Horwich A, Bell J. Mortality and cancer incidence following treatment for seminoma of the testis. Radiother Oncol 1994;30(3):193–8.
    http://www.ncbi.nlm.nih.gov/pubmed/8209001
  104. Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999;50(3):349–53.
    http://www.ncbi.nlm.nih.gov/pubmed/10392822
  105. Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scan J Urol Nephrol 1997;31(4):335–9.
    http://www.ncbi.nlm.nih.gov/pubmed/9290165
  106. Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S, Lossin P, Weissbach L; German Testicular Cancer Study Group. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumours of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003;169(5):1710–4.
    http://www.ncbi.nlm.nih.gov/pubmed/12686815
  107. Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, Newlands ES, Williams CJ. Histopathology in the prediction of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987;2(8554):294–8.
    http://www.ncbi.nlm.nih.gov/pubmed/2886764
  108. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol
    1992;10(11):1762–8.
    http://www.ncbi.nlm.nih.gov/pubmed/1403057
  109. Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, Perez DJ, Dady PJ, Forgeson GV, Kennedy IC. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand. Br J Urol Int 1999;83(1):76–82.
    http://www.ncbi.nlm.nih.gov/pubmed/10233456
  110. Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sezer B, Levay J, Robinson A, Neal DE, Williams M; Anglian Germ Cell Cancer Group. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004;63(3):556–61.
    http://www.ncbi.nlm.nih.gov/pubmed/15028457
  111. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, Persson BE, Cavallin-Stahl E, Fossa SD, Wahlqvist L. Prognostic factors in clinical stage I nonseminomatous germ cell tumours of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8(3):509–18.
    http://www.ncbi.nlm.nih.gov/pubmed/1689773
  112. Kakiashvili D, Anson-Cartwright L, Sturgeon JF, Warde PR, Chung P, Moore M, Wang L, Azuero J, Jewett MA. Non risk-adapted surveillance management for clinical stage I nonseminomatous testis tumors. J Urol 2007;177:278 (abstr 835).
  113. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, Harland SJ, Williams MV, Jakes R. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996;14(4):1106–13.
    http://www.ncbi.nlm.nih.gov/pubmed/8648364
  114. Oliver RTD, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992;148(5):1453–6.
    http://www.ncbi.nlm.nih.gov/pubmed/1279211
  115. Studer UE, Fey MF, Calderoni A. Adjuvant chemotherapy after orchidectomy in high risk patients with clinical stage I nonseminomatous testicular cancer. Eur Urol 1993;23(4):444–9.
    http://www.ncbi.nlm.nih.gov/pubmed/7687549
  116. Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumours with high risk factors. J Urol 1999;161(4):1148–52.
    http://www.ncbi.nlm.nih.gov/pubmed/10081858
  117. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14(2):441–8.
    http://www.ncbi.nlm.nih.gov/pubmed/8636755
  118. Chevreau C, Mazerolles C, Souli? M, Gaspard MH, Mourey L, Bujan L, Plante P, Rischmann P, Bachaud JM, Malavaud B. Long-term efficacy of two cycles of PEB regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004;46(2):209–14.
    http://www.ncbi.nlm.nih.gov/pubmed/15245815
  119. Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE. Fertility and sexual function following orchidectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 2001;165(2):441–4.
    http://www.ncbi.nlm.nih.gov/pubmed/11176393
  120. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13(5):1170–6.
    http://www.ncbi.nlm.nih.gov/pubmed/7537800
  121. Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit considerations in the management of clinical stage I nonseminomatous testicular tumours. Ann Surg Oncol 1996;3(1):86–93.
    http://www.ncbi.nlm.nih.gov/pubmed/8770308
  122. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25(11):1310–5.
    http://www.ncbi.nlm.nih.gov/pubmed/17416851
  123. Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J,Nilsson S, Daehlin L, Tornblom M, Smaland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Stahl E. Riskadapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997;33(7):1038–44.
    http://www.ncbi.nlm.nih.gov/pubmed/9376184
  124. Ondrus D, Matoska J, Belan V. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumours: rationale for different risk-adapted treatment. Eur Urol 1998;33(6):562–6.
    http://www.ncbi.nlm.nih.gov/pubmed/9743698
  125. Maroto P, Garc?a del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, Terrassa J, Barnadas J, Dorta J, Germ?-Lluch JR. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005;16(12):1915–20.
    http://www.ncbi.nlm.nih.gov/pubmed/16126737
  126. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-St?hl E, Solberg A, Langberg C, Bremnes R, Lauerell A, Wijkstr?m H, Klepp O: Risk-adapted treatment in clinical stage 1 (CS1), nonseminomatous germ cell testicular cancer (NSGCT), the SWENOTECA management program. JCO in press.
  127. Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel-Huinink WW, van de Vijver M, Witjes JA, Horenblas S. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumours. Urology 2002;59(6):923–9.
    http://www.ncbi.nlm.nih.gov/pubmed/12031382
  128. Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000;86(1):89–93.
    http://www.ncbi.nlm.nih.gov/pubmed/10886090
  129. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous testis cancer. J Urol 1985;134(3):485–9.
    http://www.ncbi.nlm.nih.gov/pubmed/2993672
  130. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): modifications of technique and impact on ejaculation. J Urol
    1993;149(2):237–43.
    http://www.ncbi.nlm.nih.gov/pubmed/8381190
  131. Lashley DB, Lowe BA. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25(3):405–23.
    http://www.ncbi.nlm.nih.gov/pubmed/9728211
  132. Foster RS, Roth BJ. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol 1998;25(2):145–53.
    http://www.ncbi.nlm.nih.gov/pubmed/9562447
  133. Kratzik C, Holtl W, Albrecht W et al. Risk adapted management for NSGCT stage I: long-term results of a multicenter study. J Urol 1996;155:547A.
  134. Ondrus D, Goncalves F, Kausitz J, Mat’oska J, Belan V. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumours (NSGCTT). Neoplasma 1996;43(3):195–7.
    http://www.ncbi.nlm.nih.gov/pubmed/8841507
  135. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Clinical stage B nonseminomatous germ cell testis cancer: the Indiana University experience using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995;31A(10):1599–604.
    http://www.ncbi.nlm.nih.gov/pubmed/7488408
  136. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage 1B testicular cancer? J Clin Oncol 1991;9(8):1393–8.
    http://www.ncbi.nlm.nih.gov/pubmed/2072143
  137. Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumours of the testis. J Urol 1984;131(4):677–80.
    http://www.ncbi.nlm.nih.gov/pubmed/6200611
  138. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317(23):1433–8.
    http://www.ncbi.nlm.nih.gov/pubmed/2446132
  139. Bianci G, Beltrami P, Giusti G. Unilateral laparoscopic lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm. Eur Urol 1998;33(2):190–4.
    http://www.ncbi.nlm.nih.gov/pubmed/9519363
  140. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37(3):251–60.
    http://www.ncbi.nlm.nih.gov/pubmed/10720848
  141. Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G. Laparoscopic retyroperitoneal lymph node dissection for clinical stage I non-seminomatous testicular carcinoma: long-term outcome. J Urol
    2000;163(6):1793–6.
    http://www.ncbi.nlm.nih.gov/pubmed/10799184
  142. LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumours of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165(1):89–92.
    http://www.ncbi.nlm.nih.gov/pubmed/11125371
  143. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, K?hrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008 Jun 20;26(18):2966–72. http://www.ncbi.nlm.nih.gov/pubmed/18458040
  144. Pizzocaro G, Nicolai N, Salvioni R. Marker positive clinical stage I non seminomatous germ cell tumours (NSGCT) of the testis: which primary therapy? J Urol 1996;155(Suppl):328A.
  145. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumours of the testis with serologic disease only after orchidectomy. J Urol 1994;152(1):111–3.
    http://www.ncbi.nlm.nih.gov/pubmed/7515445
  146. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol
    1997;15(2):594–603.
    http://www.ncbi.nlm.nih.gov/pubmed/9053482
  147. Garcia-del-Muro X, Maroto P, Gum? J, Sastre J, L?pez Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, P?rez X, Germ?-Lluch JR. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008 Nov 20;26(33):5416–21.
    http://www.ncbi.nlm.nih.gov/pubmed/18936476
  148. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H; German Testicular Cancer Study Group (GTCSG). Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006;17(2):276–80.
    http://www.ncbi.nlm.nih.gov/pubmed/16254023
  149. Frohlich MW, Small EJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am 1998;25(3):451–9.
    http://www.ncbi.nlm.nih.gov/pubmed/9728214
  150. Baniel J, Donohue JP. Cost and risk benefit considerations in low stage (I and II) nonseminomatous testicular tumours. AUA Update Series 1997;26:50–5.
  151. Peckham MJ, Hendry WF. Clinical stage II non-seminatous germ cell testicular tumors. Results of management by primary chemotherapy. Br J Urol 1985;57(6):763–8.
    http://www.ncbi.nlm.nih.gov/pubmed/2417652
  152. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 1985;134(6):1127–30.
    http://www.ncbi.nlm.nih.gov/pubmed/2414470
  153. Horwich A, Stenning S. Initial chemotherapy for stage II testicular nonseminoma. World J Urol 1994;12(3):148–50.
    http://www.ncbi.nlm.nih.gov/pubmed/7951341
  154. Weissbach L, Bussar-Maatz R, Fletchner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumours. Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37(5):582–94.
    http://www.ncbi.nlm.nih.gov/pubmed/10765098
  155. Sternberg CN. Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ- cell testis tumours. Urol Clin North Am 1993;20(1):93–109.
    http://www.ncbi.nlm.nih.gov/pubmed/8382000
  156. Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous germ cell tumours of the testis. J Urol 1994;151(1):72–7.
    http://www.ncbi.nlm.nih.gov/pubmed/8254836
  157. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). J Urol 1995;153(1):85–9.
    http://www.ncbi.nlm.nih.gov/pubmed/7966799
  158. Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, Lyn P, Vlamis V. Etoposide and cisplatin adjuvant therapy for patients with pathological stage II germ cell tumours. J Clin Oncol
    1995;13(11):2700–4.
    http://www.ncbi.nlm.nih.gov/pubmed/7595727
  159. Hartlapp JH, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 1987;10(1):277–84.
    http://www.ncbi.nlm.nih.gov/pubmed/2438221
  160. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumours of the testis: a follow-up of 50 patients. J Clin Oncol 1987;5(6):906–11.
    http://www.ncbi.nlm.nih.gov/pubmed/2438389
  161. Saxman S, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumours: the Indiana University Experience. J Clin Oncol 1998;16(2):702–6.
    http://www.ncbi.nlm.nih.gov/pubmed/9469360
  162. De Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15(5):1837–43.
    http://www.ncbi.nlm.nih.gov/pubmed/9164193
  163. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997;15(5):1844–52.
    http://www.ncbi.nlm.nih.gov/pubmed/9164194
  164. De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, Cook P, de Pryck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical research Council. J Clin Oncol 2001;19(6):1629–40.
    http://www.ncbi.nlm.nih.gov/pubmed/11250991
  165. Bokemeyer C, Kuczyk MA, K?hne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose intensive chemotherapy. Ann Hematol 1996;72(1):1–9.
    http://www.ncbi.nlm.nih.gov/pubmed/8605273
  166. Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ. Longterm follow-up of patients with good-risk germ cell tumours treated with etoposide and cisplatin. J Clin Oncol 1997;15(7):2553–8.
    http://www.ncbi.nlm.nih.gov/pubmed/9215824

Смотрите также

]]>
]]>